NZ: ANZMES research grants & scholarships (starting 2023)

Nick Bowden's presentation (see post #20)

Interesting talk. Lots of (preliminary) data to mull over

However, this study demonstrates yet again how difficult it is to get any representative population level data for ME

NZ has a massive research database called Integrated Data Infrastructure [IDI] which probably contains information on the colour of my kitchen sink - but it doesn't include data from primary health care

So this study could only identify ME diagnoses in Ministry of Social Development (MSD) data, i.e. the records of working-age people receiving health or disability related benefits

The study looks at a lot of things but to me the most surprising was that MSD has only 1,842 pwME receiving benefits on their record

If this number was representative - unlikely - it would suggest a prevalence of 0.06%

Interestingly pwME receiving benefits are over-represented in the least deprived areas and also in the most highly educated groups, and 94% are of European ethnicity (very out of line with the general population)

All of this suggests to me that either it's very difficult to get an ME diagnosis at all or it's very difficult to get a benefit with an ME diagnosis, or both. And ironically the people most likely to succeed are those with a higher socioeconomic background, leaving those even more vulnerable out in the cold. It's also possible that more pwME do get benefits but are hidden in the data under different diagnostic labels like mental health, fibro or FND

The researchers will be looking for community input to help interpret their results. I'm guessing that'll primarily be via ANZMES but Nick gives his email address at the end should anybody wish to comment

Female to male ratio was 7:3

Also some discussion about how to get better data in the future. The proposed registry was mentioned as well as using regionally collected primary health care diagnoses. The curly issue of diagnostic accuracy wasn't mentioned

There's a lot more data in the video but I've run out of steam
 
The study looks at a lot of things but to me the most surprising was that MSD has only 1,842 pwME receiving benefits on their record

If this number was representative - unlikely - it would suggest a prevalence of 0.06%

It wouldn't show up people supported financially by their families, then, or who are too young to work or have reached pension age.

Given the peak ages of onset—teenage years, when affected people are likely to remain with their parents, and middle age, when the loss of one income might not leave a family hard up enough to qualify for social security—that's a big gap in the data.
 
It wouldn't show up people supported financially by their families, then, or who are too young to work or have reached pension age.

Given the peak ages of onset—teenage years, when affected people are likely to remain with their parents, and middle age, when the loss of one income might not leave a family hard up enough to qualify for social security—that's a big gap in the data.
Agree. Huge data gap. To be clear, Nick stresses that they're far from capturing everyone and he doesn't believe the 0.06% is anywhere near reflecting reality. The problem is - once again - that we don't have any better data

The idea behind the study appears to be two-fold. One, see what useful information if any can be gleaned from the available data. Two, document the gaps to make a case for better data collection and epidemiological studies. Given our funding environment I'm not getting my hopes up but I guess we just have to keep on pushing
 
Lynette Hodges' presentation (post #21)

No data yet, the study still being set up & systems and equipment are being tested

It will track activities of daily living and their impact in 50 pwME. Lynette outlines all the kinds of data they're going to collect from Actigraph LEAP watches & activity diaries over 25 days. I'm not sure they've finalised how they're going to analyse all the data they're going to collect

No mention of measuring upright time, maybe the devices they're using can't measure that?
 
Nick Bowden's presentation (see post #20)

Interesting talk. Lots of (preliminary) data to mull over

However, this study demonstrates yet again how difficult it is to get any representative population level data for ME
Nick has received a grant to look into the prevalence of autism in NZ. Interesting because autism very likely also has significant diagnostic inconsistency issues that make the usual public and medical records unreliable. Unfortunately the newspaper doesn't say how Nick is planning on dealing with this problem but he has a little more money to do so (NZ$124,442) than he had for doing the same for ME (assuming he only had the ANZMES grant of $25,000, I don't actually know)

Would he have been able to get some significantly more useful ME prevalence data if he had had NZ$124,442 to play with? Or is there just no way with the available data?

I suspect the only way to get acceptably reliable data would be some updated version of that old telephone study by Jason (possibly this one from 1995? Estimating rates of chronic fatigue syndrome from a community-based sample: A pilot study). In which case NZ$124,442 wouldn't go far

Anyone know how much such a study would cost, ball park figure?

There's also the question how much the ME community should, or is willing to, spend on epidemiology vs research into pathology and treatment avenues

Reliable prevalence figures would be great to have and could support more effective advocacy, especially if they catch the currently seemingly "missing" groups (e.g. non-Caucasians). But they would be unlikely to contribute much to understanding pathology. While it's theoretically conceivable there could be a genetic signal linked to ethnicity or a signal linked to environmental exposure it would take a much larger cohort to pick those up, if they're even there, than we could ever hope to get funding for in NZ

Is there a clever way of combining an epidemiological study with a registry that would make each individual component cheaper but result in better quality data?

I'm guessing Nick is thinking about this, maybe together with Mona Jeffreys and Kahurangi Dey who're doing some feasibility(?) work into a registry as part of another ANZMES grant. If any of you are reading this, it would be great if you could join us here (there's also a private subforum option)
 
2023 application round is open 31 May - 31 July

press release: https://anzmes.org.nz/grant-and-scholarship-programme/

programme description: https://anzmes.org.nz/research-funding-programme/
There will be six funding opportunities awarded each year to Postgraduates who undertake research that furthers understanding, treatment, or prevention of ME/CFS and long COVID, including two $25,000 grants to support laboratory research studies and four $5,000 scholarships to support students undertaking research projects. Academic researchers can also apply for the grants.
It's interesting to note the wording used: the grants haven't gone to laboratory research studies.
 
2025 grant & scholarship winners announced, 1 each
”press release” said:
ANZMES is delighted to confirm that Dr. Natalia Boven of the COMPASS Research Centre at the University of Auckland has been awarded a $25,000 Grant as part of the 2025 funding round. This Grant will contribute towards the costs of her project, titled “Identifying child and adolescent predictors of adult ME/CFS and Long COVID,” which will use linked administrative data to explore the association between childhood health conditions – particularly those linked to dysfunctional mast cell activation (MCAS) – and the risk of developing ME/CFS and Long COVID in early adulthood. The research team at the University of Auckland includes Dr. Anna Brooks, Keith McLeod, Dr. Nick Bowden (a 2023 ANZMES grant recipient), Dr. Lisa Underwood, Dr. Nicola Gillies, and Dr. David Musson. This crucial study is intended to help reduce diagnostic delays, inform risk mitigation strategies, and contribute to understanding underlying pathophysiology.
”press release” said:
ANZMES is also pleased to announce Galina Mandich of the University of Otago as the recipient of a $10,000 research scholarship. The funding will support a 10-week summer research project, providing a $7,000 internship stipend and $3,000 for research materials and expenses. The study is titled: “Development of a genetic susceptibility test for developing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID: Has the large 2025 Decode ME GWAS study provided a key advance?”. The study, conducted alongside Emeritus Professor Warren Tate and Katie Peppercorn, will analyse blood samples in families where multiple members are impacted by ME/CFS and Long COVID. The aim is to identify common genetic markers or a ‘signature’ shared between them. This signature could be a significant step towards earlier diagnosis, treatment, and improved outcomes for those impacted by these debilitating conditions.
More at link
 
Last edited:
2025 grant & scholarship winners announced, 1 each
Congrats to the recipients!

First project: Not sure I understand what they’re looking for here. I very much doubt there is any sort of useful administrative data on MCAS. Did they mean mast cell activation related conditions like allergy or asthma, i.e. MCA rather than MCAS? [ETA: And what is administrative data anyway?]

Second project: I’m guessing this is an extension of, or otherwise related to, this project by the Tate group
”Tate’s donation page” said:
(B) A genetic test for susceptibility to developing ME/CFS and Long COVID

A recent technical breakthrough has revealed certain combinations of naturally occurring genetic variations in the DNA genome can account for most of the samples from ME/CFS patients in the UK biobank. These variations can account for why 5-10% of the population are susceptible to developing the post-viral sydromes, ME/CFS and Long COVID, when exposed to a triggering stress event. In preliminary studies we have shown our NZ patients also have some of these combinations of the single base variations. In 2025 we are investigating whether it is possible to develop a test for susceptibility within affected families by establishing a family molecular signature that would indicate high risk or not. We now are recruiting families to test whether such an individual family risk signature can be identified and then used to detect susceptibility among those unaffected family members. It would then be possible for those individuals at risk to take prophylactic protective measures if they were exposed to a typical triggering event like a viral infection or a major stress event, and prevent them succumbing to the long term syndromes.
 
Last edited:
Back
Top Bottom